

✓ Page 32, line 8, delete the phrase "the organic phase" and insert therefor --the aqueous phase--.

✓ Page 35, line 25, delete the phrase "3,4-dimethyl-A-" and insert therefor --3,4-dimethyl- α --.

✓ Page 36, line 12, delete the phrase "3,4-dimethyl-A-" and insert therefor --3,4-dimethyl- α --.

✓ Page 37, lines 2-3, delete the phrase "3-(3,4-dimethyl-4-(3-di-methyl-4-(3-hydroxyphenyl))" and insert therefor --3-[3,4-dimethyl-4-(3-hydroxyphenyl)--.

✓ Page 48, line 10, delete the phrase "-1-pipercliny]" and insert therefor --1-piperidiny]"--.

✓ Page 81, line 6, delete the phrase "(3-hydroxyphenol)" and insert therefor --(3-hydroxyphenyl)--.

✓ Page 86, line 7, delete the phrase "methyl)-3,4-dimethyl" and insert therefor --phenyl)-3,4-dimethyl--.

✓ Page 90, line 27, delete the phrase "2-ethyl amine" and insert therefor --2-methyl amine--.

✓ Page 91, line 24, delete the phrase "[$(\text{CH}_3)\text{COC}(\text{O})\text{N}$ " and insert therefor -- $[(\text{CH}_3)_3\text{COC}(\text{O})\text{N}$ --.

✓ Page 98, line 25, delete "t-butoxyglycine" and insert therefor --t-butoxycarbonyl glycine--.

✓ Page 99, line 7, delete " $(\text{CH}_3)_3\text{OC}(\text{O})\text{-N}$ " and insert therefor -- $(\text{CH}_3)_3\text{COC}(\text{O})\text{N}$ --.

✓ Page 101, lines 5-6, delete the phrase "and 3-2-" and insert therefor --and 3-phenyl-2---.

✓ Page 105, line 7, delete the phrase "N-dimethyl" and insert therefor --N,N-dimethyl--.

✓ Page 116, line 11, delete the phrase "4',Bromo-4,5-dimethyl-" and insert therefor --4-bromomethyl-5-methyl---.

Remarks

Applicants wish to thank Examiner Covington for allowing Claims 1-20 in parent application Serial No. 07/677,042; however, they wish to make a series of

amendments to place the case in better condition for issuance.

Applicants have amended Claim 1 in conformance with the Examiner's Amendment dated April 27, 1992. Applicants have added claims which find support, inter alia, in original Claims 2, 4, 5, and 12. Applicants respectfully submit that the amended claims are supported by the specification and do not introduce new matter.

Applicants have also amended the specification and Claim 17 to correct a series of obviously inadvertent errors. The errors were recently pointed out by Applicants' Patent Agent in China. Applicants submit that the amendments do not change the scope of the disclosure and that the amendments merely place the specification in better condition for issuance.

The amendment to the specification at page 8, line 16 corrects an administrative error which is supported by Claim 1, page 149, line 15 and by Example 94, page 115, line 2, in which R¹² must be C₁ alkyl substituted methylene to correspond to the exemplified compound.

Applicants respectfully request favorable consideration of the amended claims and passage of the case to issue.

Respectfully submitted,

Nancy J. Harrison

Nancy J. Harrison
Attorney for Applicants
Registration No. 27,083

Phone: 317-276-2308

Eli Lilly and Company
Patent Division/MVJ
Lilly Corporate Center
Indianapolis, Indiana 46285

Oct. 19, 1992